In Clinic Effectiveness of Heme Iron Polypeptide in Women with Iron Deficiency Anemia Nonresponsive or Noncompliant to Conventional Iron Supplements

Varsha Narayanan* and Amit Bhargava

1DGM Medical services, Lupin Ltd, India
2VP Medical Services, Lupin Ltd, India

Submission: August 24, 2018; Published: September 14, 2018

*Corresponding author: Varsha Narayanan, DGM- Medical Services, Lupin Ltd, Laxmi towers ‘C’, BKC, Mumbai, India; Email: varshanarayanan@lupin.com

Abstract

Background: Iron deficiency anemia affects the quality of life and productivity of women, and in pregnancy can determine and affect maternal and fetal outcomes. Though oral iron supplementation is usually first line therapy due to convenience and cost, the conventional non-heme iron oral supplements may present with gastrointestinal intolerance, poor compliance and limiting efficacy thereby compromising patient benefit. Heme iron polypeptide (HIP) supplementation may provide an alternative option for oral iron therapy due to better efficacy and tolerability seen in randomized clinical trials, therefore it would be relevant to observe if patients who have tried conventional iron supplements unsatisfactorily, can benefit from HIP in real-world setting.

Methodology: In this study, 270 women diagnosed with iron deficiency anemia, visiting gynecology clinics and who were on conventional iron supplements, with poor gastrointestinal tolerance and compliance were evaluated for their Hemoglobin (Hb) and Serum Ferritin, and then treated with daily tablets of Heme Iron polypeptide (HIP) and followed up within a month for reassessment. Hemoglobin and Serum Ferritin assessed at start of HIP therapy (baseline) were repeated at the next follow up visit along with recording patients’ tolerability to therapy.

Results: The rise in Hb was highly significant at the follow up visit in women who had baseline Hb indicating moderate and severe anemia (moderate group Hb rise in non-pregnant, pregnant: 1.15g/dl, 1.48g/dl and severe group Hb rise in non-pregnant, pregnant: 1.56g/dl, 2.75g/dl; P<0.001). There was also a significant decline in the number of patients with severe anemia, as well as those with low ferritin. The adverse event related discontinuation rate was 1% indicating a satisfactory tolerance and compliance to treatment.

Conclusion: This real-world study suggests that oral HIP therapy can be an effective treatment option in pregnant and non-pregnant women with iron deficiency anemia due to gastrointestinal tolerability, compliance and efficacy in improving hematological parameters.

Keywords: Iron deficiency anemia; Heme iron polypeptide; Hemoglobin; Compliance; Gastrointestinal tolerability

Abbreviations: HIP: Heme iron polypeptide; Hb: Hemoglobin; IDA: Iron Deficiency Anemia; GI: Gastrointestinal

Introduction

Anemia affects almost 2 billion people globally, with more than half the pregnant women and >40% of non-pregnant women in developing countries being anemic[1,2]. In India this prevalence goes up to an alarming 89.6%-100% in pregnant women[3-5].

Iron deficiency is by far the most important cause of nutritional anemia worldwide as well as in developing countries like India[6]. Poverty, social practices and food habits contribute to Dietary Iron deficiencies, while poor bioavailability and tolerability of iron supplements pose therapeutic challenges. To add, parasitic infections, closely spaced pregnancies and heavy menstrual blood losses are some of the common causes contributing to high anemia prevalence in India[7].

The recommended iron intake in non-pregnant women is at least 12mg/day however not even 10% women in India meet this requirement[8]. Anemia in pregnancy is dilutional in nature due to increasing total blood volume and red cell mass as well as increased demand from growing fetus[9]. Therefore pregnant women require a higher recommended iron intake in pregnancy of around 35 mg/day[10] which is also far from met by dietary iron alone. So, in order to maintain hemoglobin levels adequate, effective iron supplementation is essential for both maternal and
fetal well-being in pregnant women as well as for the productivity and quality of life of non-pregnant women with IDA[12].

Dietary iron is contained in two forms namely non-heme and heme. While non-heme iron supplements have been conventionally prescribed, they are associated with poor gastrointestinal (GI) tolerability and constipation, require administration on empty stomach, have varying bioavailability due to different iron salts, and interact with certain drug and food items, all of which present as major therapeutic and compliance limitations which worsen even further in pregnancy[12,13].

Heme iron, available as heme iron polypeptide (HIP) tablets for oral supplementation represents a therapeutic option for iron supplementation with lower dose requirement due to higher bioavailability and gastrointestinal tolerability[14].

Our real world in clinic data capture evaluates the effectiveness and tolerability of oral Heme Iron Polypeptide (HIP) supplementation in both non-pregnant and pregnant women with Iron deficiency anemia (IDA) who have not experienced satisfaction in therapy with conventional iron supplementation account of inability in maintaining compliance or GI tolerability.

Methodology

270 female patients with an in-clinic diagnosis of iron deficiency anemia (IDA) at gynecology clinics across India and who were on conventional iron supplements, with poor gastrointestinal tolerance and compliance, were made to discontinue their current iron supplements and re-evaluated for Hemoglobin (Hb) and serum Ferritin which were taken as baseline values. Based on the baseline Hb values patients were grouped as mild, moderate and severe anemia based on WHO cut off reference values in pregnant and non-pregnant women[15]. Patients were also classified to have low, or normal ferritin levels based on WHO cut off values[16]. Thereafter these patients with IDA were given 1-2 tablets of 12mg Heme Iron polypeptide (HIP) daily with or without meals and called for first follow up assessment visit within a month.

The patients were assessed at follow up for mean rise in the blood parameters recorded at baseline. Primary end points were mean rise in Hemoglobin and tolerability with HIP. Secondary end points included overall reduction in severity of anemia and increase in serum ferritin.

Ethical principles, patient consent and confidentiality of identity were adhered to while capturing the all patient data.

Result

Out of the 270 female patients who were prescribed HIP daily, majority (85%) patients were in the 20-40 years age group with 23 pregnant women. More than 50% patients complained of fatigue or weakness as the predominant symptom. 30% of the non-pregnant patient group had a previous history of pregnancy and a similar number in this group also gave history of heavy menstrual bleed. Gastrointestinal intolerability due to nausea, vomiting, constipation as well as no perceived improvement in symptoms were the reasons for poor compliance and unsatisfactory response to conventional iron supplements in these patients.

The mean rise in hemoglobin at first follow up visit is shown in Figure 1 & 2. At baseline, the pregnant women were all in moderate or severe anemia group and the rise in Hb at first follow up visit was 1.48g/dl and 2.75g/dl in the moderate and severe anemia group respectively (P=0.0001 and 0.0076 vs baseline). In non-pregnant women, the rise in Hb at first follow up visit was 1.02g/dl, 1.15g/dl and 1.56g/dl in the mild, moderate and severe anemia groups respectively (P<0.0001 vs baseline for moderate and severe anemia groups).

![Figure 1: Mean rise in Hb in non-pregnant women.](image1)

*P<0.0001 FU1 (1st follow up visit) vs day 0 (baseline).

WHO cut offs Hb g/dl: (non-pregnant) Normal: >12, Anemia: Mild <11.0-11.9, Moderate 10.0-11.9, Severe <10.

![Figure 2: Mean rise in Hb in Pregnant women.](image2)

*P=0.0001 FU1 (1st follow up visit) vs day 0 (baseline); !P=0.0076 FU1 vs day 0 (baseline)

WHO cut offs Hb g/dl: (pregnant) Normal: >12, Anemia: Mild <9.0-10.9, Moderate 7.0-9.9, Severe <7

The percentage of patients who had severe anemia, decreased significantly from 40% to 13% and from 19% to nil at the first follow up visit in non-pregnant and pregnant patients respectively (P<0.05) (Figure 3).

Average serum ferritin was seen to increase from 94.87 ug/dl to 109.6ug/dl, and this absolute increase was not found to be significant. However, the percentage of patients with low ferritin
levels decreased from 20% and 37.5% to 1.2% and nil in non-pregnant and pregnant women at first follow up (P<0.0001) (Figure 3). Adverse events mainly gastrointestinal disturbance, which included nausea, abdominal cramps and constipation was seen in less than 10% patients with 3 patients (1%) having to discontinue treatment.

**Discussion**

HIP is a form of iron supplementation with higher bioavailability and gastrointestinal tolerability due to higher solubility at low pH and enhanced binding to heme receptor thereby improving its cellular entry[17-19]. A 10 times higher bioavailability of heme iron compared to non-heme iron, have been reported in volunteer studies[20]. In a study where HIP, ferrous fumarate, and placebo was administered with breakfast to patients, HIP led to increased iron absorption even with meal as compared to ferrous fumarate and placebo (p < 0.03 and p < 0.02 respectively) without any side effects[20].

HIP has advantages over non-heme iron supplements as substances in food like tannins and phytates (present commonly in Indian diets) and chelators like desferrioxamine do not reduce its bioavailability unlike as seen with non-heme iron supplements[21]. A study on HIP supplementation observed significant increase in serum iron levels in subjects with low initial serum iron levels (<80μg/dl) compared to those with normal initial iron levels, suggesting that continual supplementation of heme-iron may not lead to iron overload and HIP absorption is regulated by body iron levels and heme receptor[18].

Suzuki et al evaluated the efficacy of Heme Iron Polypeptide 3 mg in pregnancy and in females with bleeding disorder and demonstrated gradual rise in Hb over a 14-week period with most patients reaching an Hb above 11g/dl with twice daily regimen[22]. Authors have suggested that average dose of 6.5 mg elemental iron as HIP or maximum dose of 9 mg elemental iron as HIP is sufficient and well tolerated to improve anemia in pregnant women when administered in the third trimester.

A recent study comparing oral HIP and intravenous iron saccharate complex in pregnant women with iron deficiency anemia (Hb < 10g/dL) showed Hb increase from 8.5 +/- 3.5 to 11.3 +/- 1.3g/dl in HIP treatment group, and an Hb increase from 8.7 +/- 2.5 to 11.7 +/- 0.9 g/dl in IV iron treatment group accompanied by increased ferritin in both groups at end of three months (no significant differences between groups for change in Hb or ferritin levels)[23]. GI upset was reported in 1.6% of patients receiving oral HIP. This suggested oral HIP as an effective and tolerable treatment which can be considered as an alternative to intravenous iron saccharate complex for iron deficiency anemia of pregnancy.

In two different studies, Young et al evaluated intrinsically radiolabeled Fe-heme and Fe non-heme (ferrous sulphate) given to pregnant women and non-pregnant women. In both pregnant and non-pregnant women, blood samples obtained 2-week post dosing to assess iron status indicators, serum hepcidin and iron utilization based on RBC incorporation of iron isotopes showed that heme-iron utilization was significantly higher relative to utilization of ferrous sulphate among both pregnant (p = 0.04) and non-pregnant women (p < 0.0001)[24].

**Figure 3:** Proportion of patients (%) with severe anemia and low ferritin.

WHO cut offs for severe anemia Hb g/dl[15]: (non-pregnant:8; pregnant 7); cut off for low ferritin/depleted iron stores: 15ug/dl[16].

How to cite this article: Varsha Narayanan, Amit Bhargava. In Clinic Effectiveness of Heme Iron Polypeptide in Women with Iron Deficiency Anemia Nonresponsive or Noncompliant to Conventional Iron Supplements. J Gynecol Women’s Health. 2018: 11(5): 555822. DOI: 10.19080/JGWH.2018.11.555822
non-heme iron utilization is inversely related to serum hepcidin (as evidenced by women with undetectable levels of serum hepcidin having significantly greater non-heme iron utilization, and a 24% variation in non-heme iron utilization seen in healthy pregnant and non-pregnant participants due to hepcidin levels), heme iron utilization is not seen to be significantly influenced by iron stores or serum hepcidin. The second study found that in pregnant women in third trimester, maternally absorbed Fe Heme tracer present in the neonates was significantly greater compared to the Fe-Non-heme tracer (p = 0.02). Also, fetal transfer was inversely associated with maternal Hb and ferritin levels, whereas total body iron significantly correlated with heme iron transfer for heme iron tracer, suggesting favourable transport across placenta.[25].

Compliance to Heme Iron therapy due to low GI side effects has been a major reason for the efficacy results in clinical studies. A study in pregnant and post-partum women noted a compliance of < 50% in 4% of the heme-iron group, 12% of the non-heme iron group and 5% of the placebo group. Women who failed to maintain an acceptable hematologic status were 10%, 20% and 45% in heme iron, non-heme iron and placebo group respectively[26]. Hb levels improved significantly only amongst strictly compliant pregnant women and anemia was significantly associated with noncompliance with iron supplementation has also been demonstrated with an adjusted OR being 6.19 (95% CI 2.55 - 15.02, p < 0.0001)[27].

Our in-clinic effectiveness studies further lend credence to results of earlier studies with HIP. The average early rise in Hb at first follow up visit itself was significant in both pregnant and non-pregnant women with IDA and as seen in our study was 1.02g/dl, 1.15g/dl and 1.56g/dl, in the baseline mild, moderate and severe anemia non-pregnant patient groups and 1.48g/dl and 2.75g/dl in the baseline moderate and severe anemia pregnant patient groups. Hb rise was seen to be more in patients with lower baseline Hb, as has also been seen in other studies. There was also a significant decline in the number of patients with severe anemia, as well as in percentage patients with low ferritin. The tolerability of HIP in our study was similar to other published studies and was better than the conventional iron supplements that the patients were on previously, with a very low treatment discontinuation rate and satisfactory patient compliance.

Conclusion

Oral HIP therapy can be an effective treatment and an option of choice for both pregnant and non-pregnant women with iron deficiency anemia especially in those patients who are non-compliant, non-responsive or poorly tolerating conventional non-heme iron supplements. HIP with its better absorption, GI tolerability and efficacy in improving hematological parameters can add to the armamentarium of IDA therapy. Further studies comparing various heme and non-heme oral iron supplements as well as also studying symptomatic improvement in a varied range of patients can further add insights in effective management of iron deficiency anemia.

References

16. WHO (2011) Serum ferritin concentrations for the assessment of iron status and iron deficiency in populations.
Journal of Gynecology and Women’s Health


Your next submission with Juniper Publishers will reach you the below assets

- Quality Editorial service
- Swift Peer Review
- Reprints availability
- E-prints Service
- Manuscript Podcast for convenient understanding
- Global attainment for your research
- Manuscript accessibility in different formats
  (Pdf, E-pub, Full Text, Audio)
- Unceasing customer service

Track the below URL for one-step submission

https://juniperpublishers.com/online-submission.php

This work is licensed under Creative Commons Attribution 4.0 License
DOI: 10.19080/JGWH.2018.11.555822

How to cite this article: Varsha Narayanan, Amit Bhargava. In Clinic Effectiveness of Heme Iron Polypeptide in Women with Iron Deficiency Anemia Nonresponsive or Noncompliant to Conventional Iron Supplements. J Gynecol Women’s Health. 2018: 11(5): 555822. DOI: 10.19080/JGWH.2018.11.555822